Effects of a commercial live vaccine for Salmonella (Typhimurium + Choleraesuis) on the prevalence of pigs carrying Salmonella at slaughter.
Live vaccine, Salmonella enterica, meat contamination.
Salmonella spp. is a zoonotic bacterium with a high prevalence in pig production, which makes it difficult to control. The challenges caused by Salmonella serovar Typhimurium and Choleraesuis in pig production involve clinical disease, subclinical disease, and contamination in the final product. One way to control this agent is with vaccination. Live vaccines are already used in the Brazilian herd with success in the control of Lawsonia intracellularis. In 2022, a commercial live vaccine for Salmonella was opened for sale in the Brazilian market. It has the two serovars that cause the most losses to pig production, the Typhimurium and the Choleraesuis serovars. Thus, this study aims to evaluate the effect of the commercial live vaccine for Salmonella (Typhimurium + Choleraesuis) on the prevalence of Salmonella in pigs at slaughter. To this end, a total of 2,000 piglets (1,000 per treatment) will be selected from litters from the same farrowing batch and separated into two treatments: vaccinated treatment, which will receive the Enterisol Salmonella T/C vaccine, and Control treatment, which will receive a saline solution. These animals will be followed until slaughter. The fecal excretion of Salmonella spp., the seroconversion to Salmonella spp., and the prevalence of pigs carrying Salmonella spp. in iliac lymph nodes at slaughter will be evaluated; the zootechnical performance (average daily gain and mortality) between vaccinated and unvaccinated pigs will also be assessed. It is expected that with vaccination, there will be a reduction in fecal excretion, increased seroconversion, a lower number of carrier pigs at slaughter, and better zootechnical performance in the vaccinated group compared to the unvaccinated group.